Altimmune, Inc. (ALT)
NASDAQ · Healthcare
Altimmune, Inc. EBITDA 2010–2025
Altimmune, Inc. annual/quarterly ebitda history and growth rate from 2010 to 2023. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Altimmune, Inc. ebitda for the quarter ending March 31, 2023 was -22.1 M, a 14.11% increase year-over-year.
- Altimmune, Inc. ebitda for the twelve months ending March 31, 2023 was -63.5 M.
- Altimmune, Inc. annual ebitda for 2022 was -87.9 M, a 8.74% decrease from 2021.
- Altimmune, Inc. annual ebitda for 2021 was -96.4 M, a 77.24% increase from 2020.
- Altimmune, Inc. annual ebitda for 2020 was -54.4 M, a 157.95% increase from 2019.
- Altimmune, Inc. annual ebitda for 2019 was -21.1 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Altimmune, Inc. EBITDA — FAQ
Altimmune, Inc. (ALT) ebitda over the last 12 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ALT's ebitda history?
The chart and table above show Altimmune, Inc.'s ebitda by year and by quarter, including the growth rate.